Research Project
Grant-in-Aid for Research Activity Start-up
The genetic alterations responsible for adverse outcomes in patients with pediatric acute myeloid leukemia (AML) remain obscure. Recent reports described NUP98-NSD1 fusion as an adverse AML prognostic marker and PRDM16 (also known as MEL1) as the representative overexpressed gene in patients harboring NUP98-NSD1 fusion. In 369 pediatric patients with de novo AML from the Japanese AML-05 clinical trial, PRDM16 gene expression levels were measured via real-time PCR, and correlations between these and other genetic alterations were investigated to clarify the clinical significance and prognostic impact. Overall, 84 of 369 patients (23%) exhibited PRDM16 overexpression. The overall (OS) and event-free survival (EFS) among PRDM16-overexpressing patients were significantly worse than those among patients with low PRDM16 expression irrespective of other cytogenetic alterations except for NPM1. PRDM16 gene expression was especially useful for stratifying FLT3-ITD-positive patients with AML.
All 2015 2014 2013
All Journal Article (6 results) (of which Peer Reviewed: 6 results, Open Access: 3 results, Acknowledgement Compliant: 1 results) Presentation (9 results)
日本小児血液がん学会雑誌
Volume: 51 Pages: 397-405
Leukemia
Volume: 29 Issue: 5 Pages: 1067-1083
10.1038/leu.2015.5
小児外科
Volume: 47 Pages: 118-122
Br J Haematol.
Volume: Epub ahead of print Issue: 3 Pages: 319-397
10.1111/bjh.13439
Haematologica
Volume: 99 Issue: 11 Pages: 225-227
10.3324/haematol.2014.107128
Genes Chromosomes Cancer
Volume: 52 Issue: 7 Pages: 683-693
10.1002/gcc.22064